Genmab A/S (NASDAQ:GMAB) Price Target Raised to $46.00

Genmab A/S (NASDAQ:GMAB) had its price target boosted by Truist Financial from $45.00 to $46.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts have also commented on GMAB. HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Sanford C. Bernstein lowered shares of Genmab A/S from a “market perform” rating to an “underperform” rating in a research report on Tuesday, April 1st. Finally, Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.80.

Genmab A/S Price Performance

Genmab A/S stock opened at $21.86 on Tuesday. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $28.56. The firm has a market capitalization of $14.02 billion, a P/E ratio of 12.42, a price-to-earnings-growth ratio of 6.56 and a beta of 0.94. The company’s 50-day moving average is $21.04 and its 200 day moving average is $20.74.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. The business had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. Research analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. purchased a new position in Genmab A/S in the fourth quarter valued at about $2,463,000. Northern Trust Corp grew its position in shares of Genmab A/S by 18.8% in the 4th quarter. Northern Trust Corp now owns 599,381 shares of the company’s stock worth $12,509,000 after buying an additional 94,858 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Genmab A/S by 1,465.3% in the 1st quarter. GAMMA Investing LLC now owns 33,482 shares of the company’s stock worth $656,000 after buying an additional 31,343 shares during the last quarter. Sei Investments Co. grew its position in shares of Genmab A/S by 55.2% in the 4th quarter. Sei Investments Co. now owns 57,702 shares of the company’s stock worth $1,205,000 after buying an additional 20,525 shares during the last quarter. Finally, LPL Financial LLC grew its position in shares of Genmab A/S by 3.3% in the 4th quarter. LPL Financial LLC now owns 195,436 shares of the company’s stock worth $4,079,000 after buying an additional 6,288 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.